Market Exclusive

Analyst Activity – Citigroup Inc. Reiterates Buy on Reata Pharmaceuticals (NASDAQ:RETA)

Analyst Ratings For Reata Pharmaceuticals (NASDAQ:RETA)

Today, Citigroup Inc. reiterated its Buy rating on Reata Pharmaceuticals (NASDAQ:RETA) with a price target of $87.00.

There are 6 buy ratings on the stock.

The current consensus rating on Reata Pharmaceuticals (NASDAQ:RETA) is Buy (Score: 3.00) with a consensus target price of $56.60 per share, a potential 59.57% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Reata Pharmaceuticals (NASDAQ:RETA)
Reata Pharmaceuticals (NASDAQ:RETA) has insider ownership of 62.40% and institutional ownership of 41.83%.

Recent Trading Activity for Reata Pharmaceuticals (NASDAQ:RETA)
Shares of Reata Pharmaceuticals closed the previous trading session at 35.35 down -0.12 -0.34% with 1,103,256 shares trading hands.

Exit mobile version